The fourth patient has been treated on February 22, 2018 in the Phase 1 study conducted by SpectraCure for the treatment of patients with relapse of prostate cancer. The treatment was performed at Princess Margaret Cancer Centre in Toronto, Canada, and passed without complications and the patient is doing well.

The treatment method, called Photodynamic Treatment (PDT), means that the patient is given a light-activated drug that accumulates in the tumor. When the cancer tissue is illuminated using SpectraCures instruments, the medicine is activated and the tumour is eliminated.

The target group of the study is patients who received relapse of high-risk prostate cancer after having radiotherapy. For this patient group, routine, curative treatment options are lacking and they are normally referred to hormone therapy to inhibit tumor growth. Hormonal treatment often causes extensive undesirable side effects. SpectraCure aims to offer a curative treatment option for these patients, with fewer and less severe side effects.

At the treatment, Dr Keith Cengel, who is the responsible physician for the clinical study in Philadelphia, was also involved. After the treatment, Cengel commented: "SpectraCures treatment system can be the Thing! This can really be the Thing that gets done on a regular basis."

For further information, please contact: SpectraCure AB publ, CEO, Masoud Khayyami, phone: +46 (0) 70 815 21 90
SpectraCure in short SpectraCure was founded in 2003 as a spin off from Lund University departments for medical laser applications and physics. The company focuses on cancer treatments using medical systems with laser light sources and reactive drugs, which is referred to as "Interstitial Photodynamic Therapy", PDT, a treatment methodology suitable for internal solid tumours of various kind, e.g. prostate and abdominal salivary glands, but also other indications such as cancer tumours in the head and neck region